IDYA · IDEAYA Biosciences, Inc.

Current Thesis

IDEAYA Biosciences' darovasertib filing and expansion trials underpin a recovery thesis that requires a weekly close above the $42.48 reference high and application completion by 2026-12-31, before a weekly close below $34. The price reference is the supplied adjusted series as of 2026-09-18; the filing deadline reflects management's guidance for the second half of 2026, reaffirmed on September 9.

The substantive development since the September 6 assessment is first-patient dosing in OptimUM-11, announced on 2026-09-09. This registrational trial evaluates darovasertib with crizotinib after local treatment of primary uveal melanoma, extending development into prevention of metastatic recurrence. Dosing establishes trial execution; the announcement contains no efficacy result from this study. The rolling new drug application (NDA) remains a separate program for metastatic disease. IDEAYA's September 9 announcement.

The narrative is maturing — an inference from the established filing story, September 9 trial milestone and September 18 close of $38.41, still below the September 4 close of $39.86. That comparison establishes weaker price confirmation, not the cause of selling or a change in institutional participation. A weekly close above the $42.48 reference high alongside new clinical evidence would overturn this assessment of stalled confirmation.

Bullish and bearish views on IDEAYA Biosciences, Inc.

The model's bull view on IDEAYA Biosciences, Inc. (IDYA), in brief: Randomized efficacy supports the filing. The bear view: Development progress precedes clinical proof. Both cases follow in full.

Bull Case

• Randomized efficacy supports the filing. The 2026-06-01 American Society of Clinical Oncology presentation reported median progression-free survival of 6.9 months with darovasertib plus crizotinib versus 3.1 months with the comparator in OptimUM-02. Objective response rates were 37.1% versus 5.8%; these results concern the studied metastatic population, not the new adjuvant setting.
• Funding supports the development program. IDEAYA's 2026-08-04 results reported approximately $1.24 billion in cash, cash equivalents and marketable securities at 2026-06-30. Management guided funding into 2030; that remains company guidance, and a subsequent reduction of the runway would weaken this part of the case.
• Another registrational design is established. The 2026-08-31 company announcement described Food and Drug Administration (FDA) agreement on the IDE849 Phase 3 design in extensive-stage small cell lung cancer. This adds a regulatory development path, while efficacy confirmation remains outstanding.

Bear Case

• Development progress precedes clinical proof. The 2026-09-09 OptimUM-11 announcement establishes treatment initiation, with relapse-free survival as the primary endpoint. It does not establish that the combination prevents recurrence. Company trial announcement.
• Clinical spending remains substantial. The 2026-08-04 results reported a second-quarter net loss of $112.5 million and research and development expense of $108.7 million. The cash balance therefore does not establish commercial profitability or remove execution risk.
• Analyst support lacks price confirmation. The supplied 2026-09-09 analyst-action report records Guggenheim raising its price target to $57. The market's 2026-09-18 close was $38.41; the analyst target is an attributed opinion, not evidence that clinical or regulatory outcomes have improved.

Setup & Price Structure

The measured 2026-09-18 adjusted close was $38.41, with a three-month price gain of 12.2% and a 9.6% distance below the $42.48 reference 52-week high. The 14-day relative strength index was 33.7. These observations describe positive medium-term performance with weaker recent momentum; they do not establish a completed base.

The $34 weekly-close threshold retains the research boundary published on 2026-09-06. It is an analytical invalidation level, not a newly measured moving average or a verified support shelf. A weekly close above $42.48 is the observable price-confirmation requirement for this recovery thesis.

Crowding cannot be established from the available observations. The September 9 Guggenheim target change is one analyst action, and the September 18 price indicators measure momentum rather than ownership concentration. Current short interest, fund flows, retail-coverage clustering and moving-average distances are missing; the sample is too small to support a positioning claim.

Catalyst Calendar (next 30 days)

For 2026-09-20 through 2026-10-20, no dated company catalyst was confirmed in the reviewed announcements. The investor-events page displayed no events when checked on September 20; this does not exclude an unscheduled filing or announcement. IDEAYA investor calendar.

• 2026-10-23 through 2026-10-27 — Clinical evidence checkpoint. Outside the next 30 days, the European Society for Medical Oncology (ESMO) congress in Madrid is the next announced data event central to the thesis. IDEAYA's 2026-07-17 announcement lists OptimUM-01 results, OptimUM-02 subgroup analysis, OptimUM-09 follow-up and partner Hengrui's IDE849 Phase 1 results; individual presentation dates were not established here. Failure to present the announced OptimUM-01 results by the congress close would remove the scheduled evidence checkpoint for the broader darovasertib case. Company ESMO announcement.
• 2026-12-31 — Filing guidance deadline. This is the end of the second-half completion window reaffirmed on 2026-09-09, not an FDA decision date. An incomplete darovasertib NDA at that deadline would invalidate the filing-timing leg. September 9 company guidance.

What Would Change Our Mind

Loss of the recovery structure would end the market thesis: a weekly close below $34 breaches the boundary retained from the September 6 assessment. Independently, failure to complete the darovasertib NDA by 2026-12-31 would break the stated filing timetable. Neither condition requires an interpretation of sentiment.

The positive case is also explicitly testable: completion of the application by 2026-12-31 and a weekly close above the September 18 reference high of $42.48 must occur before the price invalidation. The October congress supplies clinical evidence relevant to that case, but presentation alone does not establish efficacy or regulatory acceptance. No numerical success threshold for OptimUM-01 has been established in this assessment.

Correlation Notes

This assessment treats IDYA as a single-name clinical and regulatory setup. The September 18 price snapshot contains no benchmark-return series, so it cannot establish a measured correlation with biotechnology funds, interest rates or acquisition activity.

The 2026-08-19 Genentech collaboration announcement describes a study of IDE892 with a KRAS-targeted treatment in molecularly selected pancreatic cancer. That is a named development relationship, not evidence of an acquisition process or synchronized share-price behavior. The collaboration does not substantiate an acquisition premium in this thesis.